Regencell Bioscience Holdings Limited — Form 6-K Summary
Business context and reporting period
Regencell Bioscience Holdings Limited filed this Form 6-K as a foreign private issuer for November 2021. The report was filed on November 17, 2021, under Commission File Number 001-40617. The company reports annual results on Form 20-F.
Corporate governance change
Independent director Cheung Ming Wong resigned from the board effective November 16, 2021, for personal reasons. He had served as chairperson of the audit committee and as a member of the compensation and nominating committees.
The company stated that the resignation was not due to any disagreement with the company, its subsidiaries, or affiliates regarding operations, policies, or practices.
Financial metrics and material period changes
This filing does not provide revenue, profit, cash flow, margins, debt, liquidity, guidance, or other operating or financial metrics. It does not provide a financial comparison with a prior period.
Outlook, risks, and unusual items
The principal reported item is the resignation of an independent director who held key committee roles. The filing does not describe a replacement, changes to committee composition, or any related operational or financial impact.
Key facts for investors to verify
- Whether the board appointed a replacement independent director and reconstituted the audit, compensation, and nominating committees.
- Whether the company continued to satisfy applicable independence and audit committee requirements after the resignation.
- Any subsequent disclosures regarding the resignation’s effect on governance, reporting, or internal controls.
- Financial performance and liquidity information, which are not included in this Form 6-K.